Skip to main content
padlock icon - secure page this page is secure

Plasma Glucose Lowering Activity of Palmatine and its Effect on Liver, Kidney and Antioxidant Enzymes Parameters in STZ Induced Diabetic Rat Model

Buy Article:

$68.00 + tax (Refund Policy)

Diabetic mellitus is a metabolic disease primarily defined by the level of hyperglycemia that gives rise to complications such as retinopathy, nephropathy, and neuropathy. Reactive oxygen species (ROS) generation and impaired antioxidant defense systems have been implicated in the development of diabetes mellitus. Palmatine is a protoberberine alkaloid has shown potential for the treatment of hypertension, inflammation, and liver-related diseases. Our study aimed at evaluating the blood plasma glucose lowering, in vivo antioxidant, liver and profile activity of palmatine in an STZ-induced diabetic rat model. Streptozotocin (STZ) was administered by intraperitoneal injection to induce diabetes in Sprague dawley rats. A week later rats with plasma glucose level of 11mmol/L or 200mg/dL and above were orally administered with palmatine (2mg/kg) for 90 days. The blood glucose level and body weight of the rats were measured weekly. After 90 days of treatment, the rat blood was withdrawn via cardiac puncture and liver and pancreas were harvested after they were sacrificed by cervical dislocation. Palmatine significantly decreased the blood plasma glucose and lipid peroxidation compared to the positive control Tolbutamide. While the activity of the antioxidant defense system and blood parameters were normalised. Palmatine significantly (P<0.0001) reduced the blood plasma glucose level, increased the weight of the rats in palmatine treated group, plasma glucose parameters and in vivo antioxidant activity In conclusion plamatine improved blood glucose levels and reduced the oxidative stress. Therefore it may be considered in the treatment of diabetes.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Antioxidant; diabetes; histology; palmatine; plasma lowering; streptozotocin; type 2 diabetes

Document Type: Research Article

Publication date: December 1, 2015

More about this publication?
  • The journal aims to provide updates to researchers about new bioactive compounds with proven activities in various biological screenings and pharmacological models. The journal will contain information about the structures, biological activities and sources of chemical entities discovered or designed by researchers and published in leading journals. The aim is to provide a valuable information source of bioactive compounds synthesized or isolated, which can be used for further development of pharmaceuticals by industry and academia.

    The journal should prove to be essential reading for pharmacologists, pharmaceutical chemists and medicinal chemists who wish to be kept informed and up-to-date with the latest and most important developments about new bioactive compounds of natural or synthetic origin, including recent patents.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more